3d
GlobalData on MSNAdvanced Clinical chosen as CRO for Paradigm’s Phase III osteoarthritis trialParadigm Biopharmaceuticals has selected Advanced Clinical as the clinical research organisation (CRO) to support its pivotal ...
Paradigm Biopharmaceuticals continues to edge closer towards starting the pivotal phase III trial for its knee osteoarthritis ...
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
GlobalData on MSN2d
PhaseV and Alimentiv to support execution of adaptive clinical trials for GIPhaseV has formed a strategic collaboration with Alimentiv for supporting the design and execution of adaptive clinical ...
13h
GlobalData on MSNAnnovis begins treatment of subjects in Alzheimer’s trialAnnovis Bio has commenced the treatment of subjects in a Phase III clinical trial of buntanetap in treating early Alzheimer's ...
Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its ...
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...
The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from ...
GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results